LOTUSEYELotus Eye Hospital and Institute Limited
Loading LOTUSEYE price...
Peers are the listed companies in the exchange's own industry group: Hospital. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 10 Aug 2026), sales rose 26.2% from a year earlier to Rs 17.1 cr and profit rose 12.6% to Rs 0.6 cr.
- Sales grew 4 years running (Rs 38.9 cr in FY22 to Rs 53.7 cr in FY26).
- Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
- Profit fell 3 years running (Rs 4.1 cr in FY23 to Rs 0.1 cr in FY26).
- Operating margin fell from 16.2% in FY23 to 6.3% in FY26.
- Profit before interest covered interest 0.9 times in FY26 (Rs 1 cr of interest).
- Return on equity stayed under 10% from FY24 to FY26 (highest 4.9%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 19 results, the share rose on 9 and fell on 10, and moved by 3% or more on 10.
Q1 FY27: results filed 10 Aug 2026. The share went from its close on 7 Aug 2026 to its close on 11 Aug 2026 +0.81%.
Of every Rs 100 of sales in FY26, Rs 94 went on running costs, Rs 6.9 on depreciation, Rs 1.7 on interest; Rs 0.2 was left as profit.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales growthSales against the previous financial year. | - | 20.8% | 2.6% | 2.9% | 8.3% |
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | 14.9% | 16.2% | 13.5% | 7.1% | 6.3% |
| Net marginProfit after everything, per Rs 100 of sales. | 7.7% | 8.7% | 6.0% | 1.4% | 0.2% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | 7.1% | 4.9% | 1.2% | 0.1% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | 9.9% | 6.8% | 2.8% | 1.1% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | - | 0.00x | 0.00x | 0.00x | 0.19x |
| Interest coverHow many times operating profit covers the interest bill. Higher is safer. | 42.0x | 58.0x | 41.0x | 4.5x | 0.9x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 83 Cr of assets. Its owners funded 73% of that and borrowings 14%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 3 Cr, spent Rs 13 Cr on plant and equipment, and cash fell by Rs 0 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP Apollo Hospitals Enterprise Limited | 1.13 L cr | 54.0x | 11.9x | 21.8% | 19.5% | 0.57 | 8.2% | +20.6% | 0.26% |
| MAXHEALTH Max Healthcare Institute Limited | 81,266 cr | 56.0x | 7.6x | 13.6% | 12.7% | 0.32 | 16.7% | +16.7% | 0.18% |
| MANIPALHOS Manipal Health Enterprises Limited | 73,581 cr | - | - | - | - | - | - | - | - |
| FORTIS Fortis Healthcare Limited | 55,467 cr | 52.9x | 5.6x | 10.5% | 12.0% | 0.28 | 11.3% | +17.5% | 0.14% |
| NH Narayana Hrudayalaya Ltd. | 33,971 cr | 41.4x | 7.5x | 18.0% | 11.4% | 1.07 | 9.0% | +78.0% | 0.27% |
| ASTERDM Aster DM Quality Care Limited | 33,523 cr | 104.9x | 7.3x | 7.5% | 10.2% | 0.15 | 7.4% | +21.6% | 0.16% |
| MEDANTA Global Health Limited | 32,575 cr | 58.6x | 8.2x | 13.9% | 15.1% | 0.30 | 11.8% | +26.5% | 0.04% |
| KIMS Krishna Institute of Medical Sciences Limited | 28,123 cr | 131.3x | 12.5x | 7.6% | 8.2% | 1.27 | 4.6% | +35.3% | 0.74% |
| AGARWALEYE Dr. Agarwal's Health Care Limited | 15,065 cr | 102.2x | 7.4x | 8.7% | 9.7% | 0.07 | 8.4% | +26.0% | 0.01% |
| RAINBOW Rainbow Childrens Medicare Limited | 11,802 cr | 41.3x | 7.2x | 17.4% | 16.8% | 0.00 | 15.9% | +33.2% | 0.26% |
| PARKHOSPS Park Medi World Limited | 9,487 cr | - | 4.7x | - | 18.1% | 0.11 | - | - | 0.00% |
| YATHARTH Yatharth Hospital & Trauma Care Services Limited | 8,924 cr | 49.3x | 4.9x | 9.7% | 11.0% | 0.14 | 13.1% | +52.3% | 0.00% |
| HCG Healthcare Global Enterprises Limited | 8,508 cr | 367.6x | 6.4x | 2.4% | 6.9% | 0.65 | 1.3% | +13.4% | 0.00% |
| ARTEMISMED Artemis Medicare Services Limited | 4,547 cr | 40.0x | 4.9x | 12.1% | 13.7% | 0.24 | 10.2% | +12.7% | 0.13% |
| INDRAMEDCO Indraprastha Medical Corporation Limited | 2,750 cr | 20.8x | 3.7x | 25.4% | 30.7% | 0.00 | 12.3% | +11.3% | 1.49% |
| JLHL Jupiter Life Line Hospitals Limited | 1,658 cr | 8.8x | 1.1x | 12.1% | 13.8% | 0.33 | 12.0% | +18.2% | 0.40% |
| GKSL Gujarat Kidney And Super Speciality Limited | 1,400 cr | 70.8x | 5.5x | 6.6% | 8.6% | 0.06 | 16.6% | - | 0.00% |
| SHALBY Shalby Limited | 1,240 cr | 32.9x | 1.2x | 3.7% | 7.9% | 0.54 | 3.2% | +11.7% | 0.00% |
| GPTHEALTH GPT Healthcare Limited | 1,066 cr | 22.6x | 4.0x | 17.6% | 16.4% | 0.06 | 9.6% | +17.8% | 1.92% |
| LOTUSEYE Lotus Eye Hospital and Institute Limited | 236 cr | 1419.5x | 3.9x | 0.2% | 1.1% | 0.19 | 0.3% | +26.2% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from 14.9% to 6.3% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
2021 paid Rs 0.50 per share, about Rs 440 on Rs 1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.